TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.

Last updated: October 20, 2018
Sponsor: Nhat Nhat Pharmaceutical Company
Overall Status: Active - Recruiting

Phase

3

Condition

Liver Failure

Liver Disease

Treatment

N/A

Clinical Study ID

NCT03216668
TONKA-V3
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the efficacy TONKA on the reduction of ALT and AST in moderate to severe liver enzyme elevated patients; compared with Silymarin (Legalon) after 6 weeks of treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male and Female more than 18 year old.

  • Diagnosed as Alcoholic Liver Disease (ALD), or Non Alcoholic Fatty Liver Disease (NAFLD), or Liver Function Disorders due to Drugs or Chemicals.

  • ALT at baseline is in between 150 U/L to 400 U/L

  • Sign the informed consent form

Exclusion

Exclusion Criteria:

  • Hepatitis B or C.

  • Pregnant or Lactating women

Study Design

Total Participants: 140
Study Start date:
June 15, 2017
Estimated Completion Date:
September 30, 2019

Connect with a study center

  • Hue Central General Hospital

    Hue,
    Vietnam

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.